This two-day event is designed as a dedicated platform for stakeholders across the UK and European healthcare ecosystem to explore the evolving role of Real-World Evidence (RWE) in shaping market access, pricing, and reimbursement strategies.
With increasing pressure to deliver cost-effective, evidence-based care, this summit brings together thought leaders from across pharma, biotech, regulators, payers, HTA bodies, and digital health to address the regionβs most pressing access and pricing challenges.
Generating regionally compliant, high-quality evidence
Outcomes-based, managed entry, and adaptive approaches
Addressing fragmentation in pricing and reimbursement across Europe
Preparing for JCA, NICEβs Evidence Standards Framework, and evolving payer needs
Leveraging EHRs, AI, and real-time registries for faster access
Preclinical Research
Translational Research
Biomarker Discovery
Target Identification & Validation
Clinical Operations
Medical Affairs
Clinical Pharmacology
Early/Translational Clinical Programs
Clinical Biomarker Teams
Genomics/Proteomics Analysis
Companion Diagnostics Development
Regulatory Science
Companion Diagnostic Submissions
Health Authority Engagement
Preclinical Research
Translational Research
Biomarker Discovery
Target Identification & Validation
Clinical Operations
Medical Affairs
Clinical Pharmacology
Early/Translational Clinical Programs
Clinical Biomarker Teams
Genomics/Proteomics Analysis
Companion Diagnostics Development
Regulatory Science
Companion Diagnostic Submissions
Health Authority Engagement
In-depth case studies on RWE applications in European and UK HTA submissions
Strategic discussions on region-specific pricing and reimbursement frameworks
Updates on EU HTA regulation, JCA implementation, and NICE RWE standards
Exploration of AI, digital endpoints, and patient-reported outcomes in evidence generation
Networking with European regulators, payers, and market access leaders
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Christy Mullen
Agile RWE as a Strategic Lever in the Evolving Market Access Landscape
09:30 AM – 10:30 AM
Chitra Lele, Consulting Leader, Life Sciences, NTT DATA
Prasad Dindigal, Consulting Leader, Life Sciences, NTT DATA
Agile RWE as a Strategic Lever in the Evolving Market Access Landscape
09:30 AM – 10:30 AM
Chitra Lele, Consulting Leader, Life Sciences, NTT DATA
Prasad Dindigal, Consulting Leader, Life Sciences, NTT DATA




















